Semaglutide vs Pramlintide
It is the shot behind Ozempic and Wegovy, used for diabetes and weight loss. Trials in tens of thousands of people show about 15% weight loss and fewer heart attacks. A shot added to mealtime insulin in diabetes. Controlled trials show a small drop in blood sugar and weight, with more nausea and low blood sugar.
Both sit at grade A: strong human evidence. Both are FDA approved.
Evidence
AStrong human evidence
AStrong human evidence
Human studies cited
Animal or cell studies cited
Why the grade
Semaglutide has one of the largest trial programs of any peptide: the STEP trials in obesity (STEP 1, 1,961 adults), the SUSTAIN trials in type 2 diabetes, SELECT (17,604 adults with cardiovascular disease and obesity, the largest), FLOW in kidney disease, and systematic reviews pooling tens of thousands of participants. Weight loss, glucose lowering and reductions in heart attack, stroke and kidney outcomes are all shown in randomized placebo-controlled trials. What remains open is what happens over decades and how to stop without regaining.
Approval rested on randomized, placebo-controlled trials in type 1 and type 2 diabetes lasting up to a year; the label summarizes six placebo-controlled trials (four in type 1 and two in type 2 diabetes), the largest with 480 type 1 patients, in which pramlintide lowered HbA1c by about 0.25 to 0.34 percentage points more than placebo and reduced weight. The effect is real but small, and the drug has largely been displaced by GLP-1 agonists.
FDA
FDA approved
Semaglutide is FDA-approved as Ozempic (weekly injection, type 2 diabetes, 2017; with later indications to reduce cardiovascular events and, since January 2025, kidney disease progression in type 2 diabetes), Rybelsus (daily tablet, type 2 diabetes, 2019), and Wegovy (weekly injection, chronic weight management, 2021; cardiovascular risk reduction in obesity, 2024; MASH with liver fibrosis, 2025; an oral Wegovy tablet, December 2025). Compounded semaglutide is not FDA-approved.
FDA approved
Pramlintide is FDA-approved as Symlin (approved March 2005) for adults with type 1 or type 2 diabetes who use mealtime insulin and have not reached their glucose targets. The label carries a boxed warning about severe hypoglycemia, which is why insulin doses are reduced when it is started.
Sold for
Semaglutide is the GLP-1 injection behind Ozempic and Wegovy, the most talked-about weight loss drug of the decade.
Pramlintide is the only approved amylin drug, used as an add-on to mealtime insulin to blunt after-meal glucose spikes and help with weight.
Studies say
Randomized trials in tens of thousands of people show about 15 percent weight loss, roughly a 1 to 2 point HbA1c reduction, a 20 percent cut in major cardiovascular events and slower kidney decline, with gastrointestinal side effects and weight regain after stopping as the main caveats.
Randomized trials show pramlintide modestly lowers HbA1c and body weight when added to insulin, at the cost of nausea and a higher risk of insulin-related hypoglycemia, which supports its narrow approved use.
Class
GLP-1 receptor agonist
Amylin analog
Route
Several routes
Injection